ClinicalTrials.gg
Active, not recruitingNCT06870253Updated Jan 6, 2026

Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases

An observational study in Bladder Cancer and Urothelial Carcinoma Bladder, sponsored by Pangea Laboratory LLC. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Pangea Laboratory LLC · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 883 studies in Urinary Bladder Neoplasms with a site in United States — 162 open to participants now, 269 under way, 31 of them phase 3. Urinary Bladder Neoplasms · United States.

Planned enrollment
91st of 145
80 · median 180
Started
2025
with 53 others
Observational
145 of 883
41 open now
Primary completion
2027-03
later than 108 of 266 live
Registered
805th of 883
by date

Among the 883 studies in Urinary Bladder Neoplasms with a site in United States, this one is the 91st largest by planned enrollment of the 145 observational ones that give a count, is one of 54 that started in 2025, is one of 145 observational ones, reaches primary completion later than 108 of the 266 other live ones, and was the 805th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

162 of the 883 studies in Urinary Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 883 studies in Urinary Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the performance of the Bladder CARE™ Assay in patients suspected of having bladder cancer with atypical cytology or equivocal cystoscopy results. The main question it aims to answer is:

  • Does the Bladder CARE™ Assay detect bladder cancer in patients who have inconclusive cytology or cystoscopy results?

Participants will provide one voided urine specimen on the day of, and prior to, the routine, scheduled standard of care initial or repeat cystoscopy procedure. A medical records review will occur at two follow-up timepoints, (6 months and 12 months after the urine specimen collection), to document oncology-urinary-related clinical outcomes.

03

Conditions studied

  • Bladder Cancer
  • Urothelial Carcinoma Bladder

Keywords

  • Bladder CARE™
  • Bladder Cancer
  • Atypical Cytology
  • Equivocal Cystoscopy
  • Bladder Cancer Detection
  • Hematuria
  • Non-Invasive Urine Test
  • Urological
  • Urology
  • Microhematuria
  • Gross Hematuria
  • Urothelial Carcinoma
  • Bladder Cancer Biomarkers
  • Urinary Biomarker
  • Urologic Oncology
  • Inconclusive Cystoscopy Results
  • Inconclusive Cytology Results
  • Urine-Based Bladder Cancer Detection
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Urology practice

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥ 18 years of age at time of .
  2. Subject or the subject's legally authorized representative provides written informed consent.
  3. Subject is willing to follow all study procedures and available for the duration of the study.
  4. Patients with atypical cytology or equivocal cystoscopy results within 3 months before screening.
  5. Subject is scheduled for initial or repeat cystoscopy, with or without pathology.
  6. Subject is willing to provide one voided urine specimen of at least 80 ml on the same day, but prior to scheduled initial or repeat cystoscopy, with or without pathology.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or planning to become pregnant at the time of screening.
  2. Positive cystoscopy within 3 months of screening indicating presence of bladder cancer.
  3. Genitourinary manipulation (flexible or rigid cystoscopy, catheterization, urethral dilation, URS, ureteral stent) within 14 days before urine specimen collection.
  4. History of augmentation cystoplasty.
  5. History of continent cutaneous diversion or ileal conduit.
  6. History of orthotopic bladder substitution or orthotopic neobladder.
  7. Concomitant use of an drug which has been administered or may be administered within the 30 days leading up to providing or may be administered through the time of urine specimen.
  8. New or recurrent NMIBC (non-muscle invasive bladder cancer) diagnosis within three months of study enrollment.
  9. An active (bladder or other) diagnosis within 3 months of study enrollment.
  10. Patients with a history of NMIBC have undergone intravesical or infusion therapy and completed treatment less than 6 weeks prior to study enrollment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Evaluate Bladder CARE™ Assay performance for detecting bladder cancer in patients with atypical cytology or equivocal cystoscopy

    Assess the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), of the Bladder CARE™ Assay to the gold standard diagnostic methods for detecting bladder cancer in patients with atypical cytology or equivocal cystoscopy results.

    Time frame: From enrollment to the end of the study at 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — This IPD sharing plan entails sharing de-identified individual participant data (IPD) exclusively through the publication of results from this clinical trial in a reputable medical journal. The shared data will include essential de-identified demographic information such as age, gender, race/ethnicity, clinical outcomes and summary results. Additionally, the performance metrics of the Bladder CARE™ Assay will be disclosed, providing insights into its effectiveness and utility in clinical settings. By disseminating this information through a peer-reviewed journal, we aim to contribute to the scientific community's understanding of the Bladder CARE™ Assay and its implications for patient care, while ensuring that the data is contextualized within the scope of our research findings. This approach aligns with our commitment to transparency and the advancement of medical knowledge. Once accepted, the article will be published.

Time frame: Beginning 1 year after publication with no end date

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee and a signed data use agreement

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Mar 2027, 21 months after the start.

Of 203 observational studies under Urinary Bladder Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 33. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 11, 2025
StartActual
Jun 3, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06870253
Lead sponsor
Pangea Laboratory LLC
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
Jun 3, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jan 6, 2026

Study contacts

Jeffrey R. Karnes, M.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion